Treatment of cervical HPV infection and prevention of cervical cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: a. 18 years old or above; b. According to the standards of the American Cancer Society, the Colposcopy and Cervical Pathology Society, and the American Clinical Pathology Screening Guidelines, cytological abnormalities and/or hrHPV abnormalities; c. Samples can be used for methylation analysis in this project; d. The cervical histological and pathological results confirmed by this study; e. No history of cervical precancerous lesions or other cancers; f. No history of radiation therapy; g. HIV results were negative, and there was no history of organ transplantation or immunosuppression treatment; h. The patient is informed and willing to participate in the study.
Exclusion criteria
Exclusion criteria: During the research process, researchers or other authorized personnel have the right to exclude subjects who meet the following conditions: a. Poor compliance, and researchers believe that clinical research cannot be completed b. Using other medications that affect the treatment plan c. The subject is unwilling to continue clinical research and proposes to withdraw from the study d. At the review meeting, it is up to the main researchers and statisticians to decide whether to exclude the cases. The case report form that excludes the cases should be retained and archived for future reference.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Methylation levels of PAX1, EPB41L3, FAM19A4, and ZNF582 genes;accuracy;sensitivity;specificity; | — |
Countries
China
Contacts
Zhangjiagang Second People's Hospital